Mesenchymal stem cells elicits Anti-PD1 immunotherapy by targeted delivery of CX3CL1

Mesenchymal stem cells elicits Anti-PD1 immunotherapy by targeted delivery of CX3CL1

Anti-PD1/PDL1 monotherapy has failed to acquire sufficiently ideal results in most solid tumors. Mesenchymal stem cells (MSCs) have been reported to exert therapeutic effects on some tumors, but the functions of MSCs in colorectal cancer (CRC) need further research. In this study, we aimed to invest...

Full description

Bibliographic Details
Main Authors: Jize Liu, Xiaomin Ma, Chuxuan Liu, Yang Cheng, Bingjun Li, Wenjie Zhang, Runzhi Zeng, Qishuai Chen, Yun Zhang, Sanyuan Hu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Pharmacology
Subjects:
colorectal cancer
mesenchymal stem cells
anti-PD1 antibodies
macrophages
tumor microenvironment
CD8+ TCELL
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1136614/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1136614/full

Similar Items